These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 888488)

  • 1. [Metabolism of hexobarbital in patients with acute hepatitis and cirrhosis (author's transl)].
    Richter E; Gallenkamp H; Keller B; Brachtel D; Zilly W; Breimer DD
    Z Gastroenterol; 1977 Jun; 15(6):381-8. PubMed ID: 888488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug metabolism in patients with liver disease (author's transl)].
    Richter E; Epping J; Fuchshofen-Röckel M; Heusler H; Zilly W
    Leber Magen Darm; 1980 Oct; 10(5):234-40. PubMed ID: 7464410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hexobarbital-oxidation in vivo and in vitro in rats after phenobarbital-pretreatment or after portacaval anastomosis (author's transl)].
    Richter E; Gallenkamp H; Brachtel D; Grün M
    Z Gastroenterol; 1977 Jun; 15(6):389-92. PubMed ID: 888489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of famotidine after intravenous administration in liver disease.
    Ohnishi K
    Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug clearance as a decision aid for further invasive liver diagnosis--studies with hexobarbital as a model substrate].
    Zilly W; Richter E
    Z Gastroenterol; 1992 May; 30(5):325-8. PubMed ID: 1385917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caffeine clearance by two point analysis: a measure of liver function in chronic liver disease.
    Wittayalertpanya S; Israsena S; Thamaree S; Tongnopnoua P; Komolmit P
    Tokai J Exp Clin Med; 1996 Dec; 21(4-6):195-201. PubMed ID: 9300980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of age and liver disease on the disposition and elimination of diazepam in adult man.
    Klotz U; Avant GR; Hoyumpa A; Schenker S; Wilkinson GR
    J Clin Invest; 1975 Feb; 55(2):347-59. PubMed ID: 1127104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hepatic clearance of 99mTc-p-butyl HIDA in liver diseases. Correlations with routine hematochemical parameters of liver function].
    Custro N; De Francisci MC; Patanella I; Scafidi V; Indovina I
    Minerva Med; 1984 Nov; 75(42):2527-32. PubMed ID: 6083507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Half-life time or clearance of indocyanine green in patients with liver disease.
    Gilmore IT; Marigold JH; Thompson RP
    Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validity of 13C-phenylalanine breath test to evaluate functional capacity of hepatocyte in patients with liver cirrhosis and acute hepatitis.
    Koeda N; Iwai M; Kato A; Suzuki K
    Aliment Pharmacol Ther; 2005 Apr; 21(7):851-9. PubMed ID: 15801920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heme enhances hexobarbital metabolism in perfused rat liver after drug-mediated destruction of cytochrome P-450.
    Farrell GC; Gollan JL; Correia MA; Schmid R
    J Pharmacol Exp Ther; 1981 Aug; 218(2):363-7. PubMed ID: 7252836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and metabolism of theophylline in patients with liver diseases.
    Staib AH; Schuppan D; Lissner R; Zilly W; von Bomhard G; Richter E
    Int J Clin Pharmacol Ther Toxicol; 1980 Nov; 18(11):500-2. PubMed ID: 7203726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caffeine elimination in cirrhotic and non-cirrhotic liver disease of different etiology.
    Joeres R; Brachtel D; Gallenkamp H; Hofstetter G; Klinker H; Zilly W; Richter E
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():56-61. PubMed ID: 7483716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
    Ohnhaus EE; Münch U; Meier J
    Schweiz Med Wochenschr; 1976 Dec; 106(49):1748-50. PubMed ID: 1013699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered kinetics of etozolin and its active metabolite ozolinone in hepatitis and hepatic cirrhosis with ascites.
    Knauf H; Missmahl M; Schölmerich J; Gerok W; Mutschler E
    Arzneimittelforschung; 1987 Dec; 37(12):1385-8. PubMed ID: 3449068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Elimination of 75Se-selenmethionine from the plasma of patients with liver disorders (author's transl)].
    Pirwitz B
    Przegl Lek; 1979; 36(7):573-6. PubMed ID: 504707
    [No Abstract]   [Full Text] [Related]  

  • 17. [Studies on drug metabolism in obese men and mice (author's transl)].
    Grimmel K; Richter E; Zilly W
    Z Gastroenterol; 1979 Mar; 17(3):154-61. PubMed ID: 433368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hexobarbital-oxidation in vivo and in vitro in rats with bile duct ligation or ANIT-cholestasis (author's transl)].
    Brachtel D; Gallenkamp H; Richter E
    Z Gastroenterol; 1977 Jun; 15(6):378-80. PubMed ID: 888487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of manganese on hepatic drug metabolism in male and female rats.
    Schnell RC; Deimling MJ
    Res Commun Chem Pathol Pharmacol; 1984 Feb; 43(2):307-15. PubMed ID: 6709965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced renal clearance of uric acid in hepatic cirrhosis.
    Higuchi T; Nakamura T; Uchino H
    Isr J Med Sci; 1981 Nov; 17(11):1015-8. PubMed ID: 7319788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.